NCT05861050View on ClinicalTrials.gov

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Blastoid Variant Mantle Cell LymphomaMantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Glofitamab

Given IV

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Venetoclax

Given PO

Trial Locations (2)

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER